Abstract: Various embodiments include methods of diagnosing susceptibility to epilepsy in an individual or methods of managing treatment of a neurological condition in an individual, comprising: obtaining a sample from the individual; assaying the sample to determine the presence or absence of one or more biomarkers of epilepsy; and diagnosing susceptibility to epilepsy in the individual based on the presence of one or more biomarkers of epilepsy. Various embodiments further include kits for diagnostic use, comprising a diagnostic panel of one or more of the biomarkers: Let-7d-5p, miR-340-3p, miR-484, miR-151, miR-350, miR-770-5p, miR-139-3p, miR-2985, miR-101a-5p, miR-206-3p, miR-760-3p, miR-383-5p, miR-294, and miR-328a-5p.

Abstract: Embodiments for a cerebrospinal fluid flow detector for detecting the flow of cerebrospinal fluid are disclosed. In some embodiments, the cerebrospinal fluid flow detector includes a casing with a rotatable wheel having a plurality of radially extending arms disposed therein. The rotatable wheel is in communication with a channel having a distal end in communication with an inlet port and a proximal end in communication with an outlet port such that the flow of cerebrospinal fluid through the channel causes the rotatable wheel to rotate. In some embodiments, each radially extending arm includes at least one radiopaque marker in which movement of the rotatable wheel caused by fluid flow through the channel allows an X-ray imaging apparatus to detect the difference in position of a respective radiopaque marker at multiple times caused by rotation of the rotatable wheel.

Abstract: The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.

Abstract: Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease. Also described are methods, systems and compositions to distinguish between Alzheimer's disease and Parkinson's disease. In various embodiments levels of PACAP and/or SIRT3 are analyzed for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease.

Abstract: Embodiments of the invention provide a method of treating cancer, the method comprising providing a subject having cancer cells, and contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising the steps of: (a) receiving a sample of the cancer cells from the subject; (b) determining if at least a portion of the sample of the cancer cells is LKB 1 deficient; and (c) contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor.

Abstract: Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimers disease. Also described are methods, systems and compositions to distinguish between Alzheimers disease and Parkinsons disease. In various embodiments levels of PACAP and/or SIRT3 are analyzed for the diagnosis, prognosis and treatment of dementia and Alzheimers disease.

Abstract: The invention relates to diagnosis, prognosis and treatment of neurological diseases. In one embodiment, the present invention provides methods and kits that diagnose whether a subject has a neurological disease or susceptibility to a neurological disease by evaluating nuclear stress body (NSB) levels. Further described are methods and kits that prognose a neurological disease in a subject by monitoring changes in NSB levels. Also described are methods and kits that treat neurological diseases by administering one or more inhibitors of NSB signaling to a patient, as well as compositions containing one or more NSB signaling inhibitors. Medical conditions suitable with various embodiments of the invention include but are not limited to ALS, FTLD, dementia and AD.

Abstract: A system and method of detecting eye movements of a subject for the diagnosis of neurological disorders. The method includes tracking eye movements of the subject, identifying microsaccades from the tracked eye movements, and characterizing microsaccade dynamics of the identified microsaccades to determine one or more parameters, such as microsaccade direction, microsaccade velocity, microsaccade magnitude, microsaccadic peak velocity-magnitude relationship, microsaccade duration, and infersaccatic intervals. The method also includes comparing the one or more determined parameters with a corresponding control parameter, assessing the comparison to determine differences between the one or more determined parameters and the corresponding control parameters, and generating a report including the diagnosis of neurological disorder based on the assessment.

Abstract: Tetrahydroberberine (THB), isolated from the Chinese herb “Corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (THB), THB analogs or derivatives, tetrahydroprotoberberines (THPB). Tetrahydroberberine (THB) and analogs such as l-stepholidine (l-SPD) potently block functional KATP channels natively expressed on midbrain dopamine neurons. Further, THB also blocks pancreatic ?-cell KATP channels, and can be developed to a novel drugs for treating disease and/or conditions such as diabetes and Parkinson's disease.

Abstract: Described here are systems and methods for estimating bulk rotation and translation of an imaged subject between different blades in a PROPELLER MRI or similar sequence. Correlations between unique pairs of blades are calculated and the relative shift values that maximize the correlation between each pair of blades are identified as relative shift values to be applied for motion correction. Using this method, no reference blade is required, nor does a computationally expensive iterative process need to be performed.

Abstract: The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.

Abstract: A system and method for bending a surgical rod using an automated bending system includes receiving an indication of a plurality of line segments defined on the rod and an indication of an angle measurement to be formed between at least two adjacent ones of the plurality of line segments. Bending parameters to perform on the rod to form the angle measurement between the at least two adjacent ones of the plurality of line segments are determined and operation of the automated bending system is controlled using the bending parameters to create an angle having the angle measurement between the at least two adjacent ones of the plurality of line segments.

Abstract: Systems and methods for producing cervical ripening in a pregnant patient. The method includes generating an electrical stimulation current between about 0.01 milliamperes and about 6 milliamperes using a current unit, coupling an electrode probe to the current unit, and inserting the electrode probe transvaginally so that at least one electrode of the electrode probe is in contact with the patient's cervix. The method also includes applying the electrical stimulation current from the current unit through the electrode probe and the at least one electrode to the patient's cervix to produce ripening of the patient's cervix.

Abstract: A system and method for determining a subject's attentional response to a stimulus. The method includes measuring microsaccadic eye movement dynamics of the subject, detecting whether a microsaccadic signature (a suppression in microsaccadic rate) is present in the measured microsaccadic eye movement relative to a time of the stimulus, and correlating the subject's attentional response to the stimulus based on the detection. The method further includes determining that the stimulus was sensed if the microsaccadic signature is present and determining that the stimulus was not sensed if the microsaccadic signature is absent.

Abstract: The present application relates to the use of a pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating an autoimmune disease by administering pertussis toxin to the individual. In another embodiment, the autoimmune disease is multiple sclerosis. In another embodiment, the invention provides a method of treating a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease by administering pertussis toxin, or a derivative, analog, salt or pharmaceutical equivalent.

Abstract: A system and method for determining a subject's level of fatigue. The method includes measuring microsaccadic eye movement dynamics of the subject, calculating a current microsaccade peak velocity from the measured microsaccadic eye movement dynamics, and comparing the current microsaccade peak velocity to a baseline microsaccade peak velocity. The method further includes determining the level of fatigue based on a difference between the current microsaccade peak velocity and the baseline microsaccade peak velocity.

Abstract: Some embodiments of the invention provide a system and method for treating insufficient uterine contractions after labor and delivery. The system includes a control module and a current source controlled by the control module to produce stimulating current at a frequency greater than or equal to about 5.0 Hertz. The system also includes one or more stimulation electrodes to provide the stimulating current to the patient in order for the patient to produce tonic uterine contractions.

Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.

Abstract: Systems and methods for detecting deceptive intent of a subject include observing eye movements of the subject and correlating the observed movements to known baseline neurophysiological indicators of deception. A detection system may record eye movement data from the subject, compare the eye movement data to a data model comprising threshold eye movement data samples, and from the comparison make a determination whether or not the subject is lying. The detection system may create an alert if deception is detected. The eye movements detected include saccadic and intersaccadic parameters such as intersaccadic drift velocity. Measurements may be collected in situ with a field testing device, such as a non-invasive, non-contact device attached to the subject's computing device and configured to non-obtrusively record the eye movement data.

Abstract: The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.